John S. Tregoning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
John S. Tregoning has a total of 638 co-authors. Here are the top co-authors by number of shared publications:
- Peter J. M. Openshaw
National Heart and Lung Institute, Imperial College London, London, UK
19 shared publications - James. A. Harker
National Heart and Lung Institute, Imperial College London, London, UK
12 shared publications - Robin J. Shattock
Department of Infectious Disease, Imperial College London, SW7 2AZ, UK
12 shared publications Ekaterina Kinnear
Department of infectious disease, Imperial College London, London, UK
10 shared publicationsRobin J. Shattock
8 shared publicationsBelinda Wang
Department of Respiratory Medicine, The Centre for Respiratory Infection and the MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, National Heart and Lung Institute, Imperial College London, London, United Kingdom
7 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10028
Tuning intracellular immunity by Nodamura virus B2 protein enhances self-amplifying RNA activity
Self-amplifying RNA (saRNA) offers a powerful approach for vaccine development, as its replicative nature within cells provides prolonged antigen expression together with self-adjuvanticity. However, its potency is often limited by innate immune responses, particularly those triggered by intracellular double-stranded RNA (dsRNA), highlighting the need for strategies that can boost saRNA efficacy without compromising its immunostimulatory properties. Here we show that the cis -expression of the Nodamura virus (NoV) B2 protein markedly enhances saRNA-driven transgene expression by alleviating key cell-intrinsic antiviral effectors. In stem cells, NoV B2 limits the accumulation of Dicer-generated viral small RNAs, consistent with suppression of antiviral RNA interference, while in somatic cells, it prevents protein kinase R (PKR)-driven translational shutdown. NoV B2 sequesters dsRNA at the cell periphery, shielding it from antiviral effectors without suppressing type I interferon induction or signalling, thereby preserving saRNA’s immunostimulatory properties, while enhancing its transgene expression potential. These findings reveal a strategy to overcome intracellular antiviral restriction of saRNA while preserving adjuvanticity, with implications for the design of more effective saRNA-based vaccines and therapeutics.
- 28 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10028
Open AccessTuning intracellular immunity by Nodamura virus B2 protein enhances self-amplifying RNA activity
Self-amplifying RNA (saRNA) offers a powerful approach for vaccine development, as its replicative nature within cells provides prolonged antigen expression together with self-adjuvanticity. However, its potency is often limited by innate immune responses, particularly those triggered by intracellular double-stranded RNA (dsRNA), highlighting the need for strategies that can boost saRNA efficacy without compromising its immunostimulatory properties. Here we show that the cis -expression of the Nodamura virus (NoV) B2 protein markedly enhances saRNA-driven transgene expression by alleviating key cell-intrinsic antiviral effectors. In stem cells, NoV B2 limits the accumulation of Dicer-generated viral small RNAs, consistent with suppression of antiviral RNA interference, while in somatic cells, it prevents protein kinase R (PKR)-driven translational shutdown. NoV B2 sequesters dsRNA at the cell periphery, shielding it from antiviral effectors without suppressing type I interferon induction or signalling, thereby preserving saRNA’s immunostimulatory properties, while enhancing its transgene expression potential. These findings reveal a strategy to overcome intracellular antiviral restriction of saRNA while preserving adjuvanticity, with implications for the design of more effective saRNA-based vaccines and therapeutics.
- Open Access
Spatiotemporal control of STING activation and saRNA delivery decouples humoral and cellular immunity
Self-amplifying mRNA (saRNA) vaccine formulations link the location and timing of antigen expression to innate immune stimulation by both RNA cargo and carrier. We hypothesized that targeting a polymeric STING agonist prodrug (polySTING) to antigen-presenting cells (APCs) independently of saRNA delivery could tune vaccines responses without limiting saRNA expression. By varying the time and location of STING signaling relative to saRNA delivered by muscle-restricted (polyplex, PP) and lymph node-draining (lipid nanoparticle, LNP) saRNA formulations, we studied how spatiotemporal colocalization of type I interferon (IFN-I) and antigen expression impacts innate and adaptive vaccine responses. Co-administering PP + polySTING decreased antigen-specific adaptive type 1 responses by mismatching early lymph node IFN-I and later arriving antigen; this could be reversed by delaying polySTING delivery timing. Conversely, synchronizing early LNP saRNA delivery and polySTING IFN-I in the lymph node boosted saRNA type 1 T cell responses without impacting humoral immunity, which re-directed antigen-intrinsic immune skewing and enhanced protection against pulmonary Acinetobacter baumannii challenge. Collectively, these findings define formulation-specific innate immune responses to saRNA vaccines and establish APC-targeted adjuvants as a strategy to tune saRNA vaccine immunogenicity.
Open AccessSpatiotemporal control of STING activation and saRNA delivery decouples humoral and cellular immunity
Self-amplifying mRNA (saRNA) vaccine formulations link the location and timing of antigen expression to innate immune stimulation by both RNA cargo and carrier. We hypothesized that targeting a polymeric STING agonist prodrug (polySTING) to antigen-presenting cells (APCs) independently of saRNA delivery could tune vaccines responses without limiting saRNA expression. By varying the time and location of STING signaling relative to saRNA delivered by muscle-restricted (polyplex, PP) and lymph node-draining (lipid nanoparticle, LNP) saRNA formulations, we studied how spatiotemporal colocalization of type I interferon (IFN-I) and antigen expression impacts innate and adaptive vaccine responses. Co-administering PP + polySTING decreased antigen-specific adaptive type 1 responses by mismatching early lymph node IFN-I and later arriving antigen; this could be reversed by delaying polySTING delivery timing. Conversely, synchronizing early LNP saRNA delivery and polySTING IFN-I in the lymph node boosted saRNA type 1 T cell responses without impacting humoral immunity, which re-directed antigen-intrinsic immune skewing and enhanced protection against pulmonary Acinetobacter baumannii challenge. Collectively, these findings define formulation-specific innate immune responses to saRNA vaccines and establish APC-targeted adjuvants as a strategy to tune saRNA vaccine immunogenicity.
- Open Access
- 4 August 2026
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 24 (8) , e3003912
Is the scientific paper still a fraud?
How we write scientific papers does not reflect how we do science. Their formal structure infers a pre-ordained linear process rather than reflecting the messy creativity of research. This matters in the AI age because it masks the human in the process.
- 4 August 2026
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 24 (8) , e3003912
Open AccessIs the scientific paper still a fraud?
How we write scientific papers does not reflect how we do science. Their formal structure infers a pre-ordained linear process rather than reflecting the messy creativity of research. This matters in the AI age because it masks the human in the process.
- Open Access
- 20 February 2026
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (1)
Systems vaccinology analysis of saRNA immunization identifies an acute innate immune signature correlated with adaptive immunity
- 20 February 2026
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (1)
Open AccessSystems vaccinology analysis of saRNA immunization identifies an acute innate immune signature correlated with adaptive immunity
- 12 February 2026
- Published by Springer Nature in Nature
- Vol. 650 (8102) , 525
Science funding needs fixing — but not through chaotic reforms
- 12 February 2026
- Published by Springer Nature in Nature
- Vol. 650 (8102) , 525
Science funding needs fixing — but not through chaotic reforms
- Open Access
- 31 January 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (3) , 106696
Comparative cross-species transcriptomics during RSV infection identifies targets to treat RSV disease
- 31 January 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (3) , 106696
Open AccessComparative cross-species transcriptomics during RSV infection identifies targets to treat RSV disease
- Open Access
- 19 November 2025
- Published by Springer Nature in Research Square
An integrated in silico and in vitro genotype to phenotype pipeline to predict and characterise new RSV F site zero escape mutants
The new respiratory syncytial virus (RSV) interventions target the Fusion (F) protein and may therefore impose a selective pressure upon the F gene. Identifying monoclonal antibody-resistant mutants (MARMs) of concern is a priority to ensure continued antibody effectiveness. Here we evaluated genomes of RSV isolates sampled in the UK prior to vaccine or nirsevimab implementation. We observed a low frequency of the K68E mutation in site Ø which we confirmed had increased resistance to a nirsevimab-like monoclonal antibody. To predict other MARMs of concern we used bioinformatic tools to model the interface between nirsevimab and RSV-F. There was a very strong correlation between antibody-antigen Kd and in vitro neutralisation data. Performing in silico deep mutational scanning of each viral contact residue identified new mutations of concern in RSV-A (N63T, I64V, D200E, K201N) which are already circulating; increased resistance to a site Ø targeting antibody was confirmed using reverse genetics derived RSV. To explore the universality of the pipeline, we also tested correlations between predicted and actual binding for licensed antibodies targeting SARS-CoV-2. We therefore demonstrate the ability to determine previously unidentified escape mutations in silico and flag them for further surveillance.
- 19 November 2025
- Published by Springer Nature in Research Square
Open AccessAn integrated in silico and in vitro genotype to phenotype pipeline to predict and characterise new RSV F site zero escape mutants
The new respiratory syncytial virus (RSV) interventions target the Fusion (F) protein and may therefore impose a selective pressure upon the F gene. Identifying monoclonal antibody-resistant mutants (MARMs) of concern is a priority to ensure continued antibody effectiveness. Here we evaluated genomes of RSV isolates sampled in the UK prior to vaccine or nirsevimab implementation. We observed a low frequency of the K68E mutation in site Ø which we confirmed had increased resistance to a nirsevimab-like monoclonal antibody. To predict other MARMs of concern we used bioinformatic tools to model the interface between nirsevimab and RSV-F. There was a very strong correlation between antibody-antigen Kd and in vitro neutralisation data. Performing in silico deep mutational scanning of each viral contact residue identified new mutations of concern in RSV-A (N63T, I64V, D200E, K201N) which are already circulating; increased resistance to a site Ø targeting antibody was confirmed using reverse genetics derived RSV. To explore the universality of the pipeline, we also tested correlations between predicted and actual binding for licensed antibodies targeting SARS-CoV-2. We therefore demonstrate the ability to determine previously unidentified escape mutations in silico and flag them for further surveillance.
- Open Access
- 8 September 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (12) , 5945-5964
Immunology of RNA-based vaccines: The critical interplay between inflammation and expression
- 8 September 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (12) , 5945-5964
Open AccessImmunology of RNA-based vaccines: The critical interplay between inflammation and expression
- Open Access
- 4 July 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 1-14
Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease
Vaccines are central to the strategy to control antimicrobial resistant (AMR) bacterial infections; one multidrug resistant pathogen of particular concern is Acinetobacter baumannii. In this study we identified two novel A. baumannii antigens using mass spectrometry and phage expression: Oxa23 and PAL. These genes are highly conserved between different isolates of A. baumannii and recognised by convalescent human sera. We explored their protective immunity using two different vaccine platforms, recombinant outer membrane vesicles (rOMV) and mRNA. RNA vaccine immunised mice had significantly reduced bacterial load in their lower airways following challenge with carbapenem resistant A. baumannii, with Oxa23 providing better protection than PAL. We then compared routes of delivery and RNA vaccine platforms, demonstrating that intranasally delivery of mRNA encoding OXA-23 (formulated with GL67A) significantly reduced disease severity and enhanced bacterial clearance. These studies validate in silico identified antigens through challenge studies and novel mucosal vaccine delivery approaches.
- 4 July 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 1-14
Open AccessIntranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease
Vaccines are central to the strategy to control antimicrobial resistant (AMR) bacterial infections; one multidrug resistant pathogen of particular concern is Acinetobacter baumannii. In this study we identified two novel A. baumannii antigens using mass spectrometry and phage expression: Oxa23 and PAL. These genes are highly conserved between different isolates of A. baumannii and recognised by convalescent human sera. We explored their protective immunity using two different vaccine platforms, recombinant outer membrane vesicles (rOMV) and mRNA. RNA vaccine immunised mice had significantly reduced bacterial load in their lower airways following challenge with carbapenem resistant A. baumannii, with Oxa23 providing better protection than PAL. We then compared routes of delivery and RNA vaccine platforms, demonstrating that intranasally delivery of mRNA encoding OXA-23 (formulated with GL67A) significantly reduced disease severity and enhanced bacterial clearance. These studies validate in silico identified antigens through challenge studies and novel mucosal vaccine delivery approaches.
- Open Access
- 2 July 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102585
Manipulating the delivery and immunogenicity of DNA vaccines through the addition of CB[8] to cationic polymers
- 2 July 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102585
Open AccessManipulating the delivery and immunogenicity of DNA vaccines through the addition of CB[8] to cationic polymers